The oral corticosteroid-sparing effect of omalizumab in children with severe asthma

Archives of Disease in Childhood

Volumn 97, Issue 7, 2012, Pages 604-609

  Brodlie, Malcolm ^a,b   McKean, Michael C ^b   Moss, Samantha ^b   Spencer, David AAnthony ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; PREDNISOLONE;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; CHILDHOOD ASTHMA CONTROL TEST; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAINTENANCE THERAPY; MINI ASTHMA QUALITY OF LIFE QUESTIONNAIRE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; INJECTIONS, SUBCUTANEOUS; PREDNISOLONE; PSYCHOMETRICS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84863307371     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2011-301570     Document Type: Article

References (29)

1. Sennhauser FH, Braun-Fahrländer C, Wildhaber JH. The burden of asthma in children: a European perspective. Paediatr Respir Rev 2005;6:2-7. (Pubitemid 40220860)
2. British Guideline on the Management of Asthma. A national clinical guideline. British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2011.
3. Bush A, Saglani S. Management of severe asthma in children. Lancet 2010;376:814-25.
4. Hedlin G, Bush A, Lødrup Carlsen K, et al.; Problematic Severe Asthma in Childhood Initiative group. Problematic severe asthma in children, not one problem but many: a GA2LEN initiative. Eur Respir J 2010;36:196-201.
5. Bracken M, Fleming L, Hall P, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child 2009;94:780-4.
6. Lødrup Carlsen KC, Hedlin G, Bush A, et al.; PSACI (Problematic Severe Asthma in Childhood Initiative) group. Assessment of problematic severe asthma in children. Eur Respir J 2011;37:432-40.
7. Bush A, Lenney W, Spencer D, et al. Not NICE: a better way forward? Arch Dis Child 2011;96:907-8.
8. Bush A, Pedersen S, Hedlin G, et al.; PSACI (Problematic Severe Asthma in Childhood Initiative) group. Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where? Eur Respir J 2011;38:947-58.
9. Covar RA, Leung DY, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000;106:651-9.
10. Fleming L, Wilson N, Bush A. Difficult to control asthma in children. Curr Opin Allergy Clin Immunol 2007;7:190-5. (Pubitemid 46411522)
11. Vuillermin PJ, Brennan SL, Robertson CF, et al. Anxiety is more common in children with asthma. Arch Dis Child 2010;95:624-9.
12. Lenney W. The burden of pediatric asthma. Pediatr Pulmonol Suppl 1997;15:13-16. (Pubitemid 27415253)
13. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001;164:S6-11.
14. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;2:CD003559.
15. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
16. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210-16.
17. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-15.
18. NICE. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years, 2010.
19. Scottish Medicines Consortium. Omalizumab advice, 2010.
20. Brodlie M, McMurray A, Crofton PM, et al. Strategies to screen for adrenal suppression in children with asthma should take account of compliance with inhaled corticosteroids. Eur J Pediatr 2007;166:493-4. (Pubitemid 46450482)
21. Xolair (omalizumab) prescribing information. Novartis Pharmaceuticals Corporation, 2010.
22. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
23. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 1996;5:35-46. (Pubitemid 26100501)
24. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007;119:817-25. (Pubitemid 46527825)
25. Schatz M, Zeiger RS, Mosen D, et al. Asthma-specific quality of life and subsequent asthma emergency hospital care. Am J Manag Care 2008;14:206-11. (Pubitemid 351501859)
26. Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009;124:719-23.e1.
27. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
28. Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993;68:356-9. (Pubitemid 23084586)
29. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008;372:2152-61.